Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Do you have a new diagnosis of Acute Myeloid Leukemia and are looking for another treatment option? In this study, we are looking to see if the study drug (Tagraxofusp) can help control Leukemia or achieve remission.

Have you been recently diagnosed with follicular lymphoma (a type of non-Hodgkin lymphoma)? You may be able to take part in a research study to learn more about the safety and tolerability of an experimental drug called odronextamab.

Have you been diagnosed with unfavorable risk prostate cancer? Are you looking for treatment options? If so, you may be able to participate in a clinical trial examining different treatment options for prostate cancer.

Do you plan to undergo radiation therapy for a cancer in the abdomen or pelvic region? You may be able to take part in a research study to help us learn if a fatty acid supplement can improve quality of life by limiting GI upset during radiation therapy.

Do you have stage 1, HER2-positive breast cancer? Has your surgery already been completed? If so, you may be able to take part in a study to help us learn more about a combination of medications to treat your cancer.

Have you been recently diagnosed with Acute Lymphoblastic Leukemia? If so, you may be able to take part in a research study to help us learn more about the effects of using Tyrosine Kinase Inhibitor (TKI), steroids and blinatumomab versus treatment with steroids, Tyrosine Kinase Inhibitor (TKI) and chemotherapy.

Do you have metastatic or recurrent lung cancer? Have you already been treated with chemotherapy or immunotherapy? If so, you may qualify for the LungMap protocol, which will help us identify clinical trials you may be eligible for.